Skip to main content
SpringerLink
Log in

Cationorm® (cationic emulsion eye drops) in dry eye disease: a guide to its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Cationorm® is a unique preservative-free option for the treatment of the symptoms of dry eye that offers some advantages over conventional artificial tears. The electrostatic interaction between the positively charged Cationorm® emulsion and the negatively charged cells on the ocular surface prolongs the residence time on the ocular surface. Moreover, as an oily emulsion, Cationorm® augments all three layers of tear film (i.e. lipid layer, aqueous coating and mucin layer), thereby stabilizing the tear film and providing beneficial moisturizing and lubricating effects. Overall, the efficacy and tolerability/safety profiles of Cationorm® in treating mild to severe dry eye disease in clinical trials are similar to, or better than, those of other artificial tears.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Marshall LL, Roach JM. Treatment of dry eye disease. Consult Pharm. 2016;31(2):96–106.

    Article  PubMed  Google Scholar 

  2. Fiscella RG. Understanding dry eye disease: a managed care perspective. Am J Manag Care. 2011;17(Suppl 16):S432–9.

    PubMed  Google Scholar 

  3. The definition and classification of dry eye disease. report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92.

    Article  Google Scholar 

  4. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93–107.

  5. Foulks GN. Pharmacological management of dry eye in the elderly patient. Drugs Aging. 2008;25(2):105–18.

    Article  CAS  PubMed  Google Scholar 

  6. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21(4):310–6.

    PubMed  Google Scholar 

  7. Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922–9.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012;31(5):472–8.

    Article  PubMed  Google Scholar 

  9. Skalicky SE, Petsoglou C, Gurbaxani A, et al. New agents for treating dry eye syndrome. Curr Allergy Asthma Rep. 2013;13(3):322–8.

    Article  CAS  PubMed  Google Scholar 

  10. Lienart JP, Tarko L, Uchino M, et al. Long-term natural history of dry eye disease from the patient’s perspective. Ophthalmology. 2016;123(2):425–33.

    Article  Google Scholar 

  11. Tong L, Petznick A, Lee S, et al. Choice of artificial tear formulation for patients with dry eye: where do we start? Cornea. 2012;31(Suppl 1):S32–6.

    Article  PubMed  Google Scholar 

  12. Georgiev GA, Yokoi N, Ivanova S, et al. Surface chemistry of the interactions of cationic nanoemulsions with human meibum films [poster]. In: The Annual meeting of the Association for Research in Vision and Ophthalmology; 2016.

  13. Cationorm eye drop emulsion: patient information [in German]. Munich: Santen GmbH; 2013.

  14. Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, Novasorb. J Drug Del. 2012;2012:604204. doi:10.1155/2012/604204.

    Google Scholar 

  15. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66(4):531–41.

    Article  CAS  PubMed  Google Scholar 

  16. Daull P, Feraille L, Elena PP, et al. Comparison of the anti-inflammatory effects of artificial tears in a rat model of corneal scraping. J Ocul Pharmacol Ther. 2016;32(2):109–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kinnunen K, Kauppinen A, Piippo N, et al. Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures. Exp Eye Res. 2014;120:82–9.

    Article  CAS  PubMed  Google Scholar 

  18. Binlich F, Baudouin C, Pisella PJ, et al. A noval cationic emulsion, Cationorm, for treatment of patients with bilateral moderate dry eye syndrome [abstract]. Invest Ophthalmol Vis Sci. 2006;47(13):254.

    Google Scholar 

  19. Amrane M, Creuzot-Garcher C, Robert PY, et al. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease: a randomised comparative study. J Fr Ophtalmol. 2014;37(8):589–98.

    Article  CAS  PubMed  Google Scholar 

  20. Aragona P, Spinella R, Rania L, et al. Assessment of the efficacy of Cationorm® in patients with moderate dry eye compared with Optive® and Emustil® eye drops [abstract no. 3125]. Acta Ophthalmologica. 2011;89(Suppl s248).

  21. Ismail D, Amrane M, Robert P-Y, et al. Efficacy of Cationorm® preservative-free cationic emulstion versus Vismed® (0.18% hyaluronic acid) in mdoerate to severe dry eye disease (DED) patients [slide presentation]. Evry, France: Santen SAS; 2016.

  22. du Toit LC, Pillay V, Choonara YE, et al. Ocular drug delivery: a look toward nanobioadhesives. Expert Opin Drug Del. 2011;8(1):71–94.

    Article  Google Scholar 

  23. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163–78.

Download references

Acknowledgments

The manuscript was reviewed by R. G. Fiscella, Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL, USA. During the peer review process, the manufacturer of Cationorm® was offered an opportunity to comment on the article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

K. A. Lyseng-Williamson is a salaried employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A. Cationorm® (cationic emulsion eye drops) in dry eye disease: a guide to its use. Drugs Ther Perspect 32, 317–322 (2016). https://doi.org/10.1007/s40267-016-0319-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-016-0319-0

Keywords

Search

Navigation